A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints
- PMID: 27438833
- PMCID: PMC4964524
- DOI: 10.3390/ijms17071151
A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints
Abstract
Interference of the binding of programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) has become a new inspiring immunotherapy for resisting cancers. To date, the FDA has approved two PD-1 monoclonal antibody drugs against cancer as well as a monoclonal antibody for PD-L1. More PD-1 and PD-L1 monoclonal antibody drugs are on their way in clinical trials. In this review, we focused on the mechanism of the PD-1/PD-L1 signaling pathway and the monoclonal antibodies (mAbs) against PD-1 and PD-L1, which were approved by the FDA or are still in clinical trials. And also presented is the prospect of the PD-1/PD-L1 immune checkpoint blockade in the next generation of immunotherapy.
Keywords: Immunotherapy; PD-1 (Programmed cell death protein 1); PD-L1 (Programmed death-ligand 1); monoclonal antibodies (mAbs).
Figures
Similar articles
-
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29. Clin Ther. 2015. PMID: 25823918 Free PMC article. Review.
-
PD-1/PD-L1 and immunotherapy for pancreatic cancer.Cancer Lett. 2017 Oct 28;407:57-65. doi: 10.1016/j.canlet.2017.08.006. Epub 2017 Aug 18. Cancer Lett. 2017. PMID: 28826722 Review.
-
Anti-PD-1 and Anti-PD-L1 Monoclonal Antibodies in People Living with HIV and Cancer.Curr HIV/AIDS Rep. 2020 Oct;17(5):547-556. doi: 10.1007/s11904-020-00525-y. Curr HIV/AIDS Rep. 2020. PMID: 32827111 Free PMC article. Review.
-
Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. doi: 10.1021/acs.jmedchem.8b00990. Epub 2018 Oct 9. J Med Chem. 2019. PMID: 30247903 Review.
-
PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.Oncologist. 2019 Feb;24(Suppl 1):S31-S41. doi: 10.1634/theoncologist.2019-IO-S1-s05. Oncologist. 2019. PMID: 30819829 Free PMC article. Review.
Cited by
-
Immunotherapy in melanoma: advances, pitfalls, and future perspectives.Front Mol Biosci. 2024 Jun 28;11:1403021. doi: 10.3389/fmolb.2024.1403021. eCollection 2024. Front Mol Biosci. 2024. PMID: 39086722 Free PMC article. Review.
-
Transcriptomics analysis of LINC02202/XBP1 axis in melanoma: Implications for drug targeting and PD-1 monoclonal antibody efficacy.J Cell Mol Med. 2024 Apr;28(8):e18247. doi: 10.1111/jcmm.18247. J Cell Mol Med. 2024. PMID: 38520212 Free PMC article.
-
Nivolumab Plus 5-Azacitidine in Pediatric Relapsed/Refractory Acute Myeloid Leukemia (AML): Phase I/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium.Cancers (Basel). 2024 Jan 24;16(3):496. doi: 10.3390/cancers16030496. Cancers (Basel). 2024. PMID: 38339248 Free PMC article.
-
Mapping the epitope of PD-L1 to the paratope of the antibody durvalumab using molecular dynamics simulation.Am J Transl Res. 2024 Jan 15;16(1):85-97. doi: 10.62347/ISDD4626. eCollection 2024. Am J Transl Res. 2024. PMID: 38322578 Free PMC article.
-
Hypopituitarism induced by pembrolizumab plus axitinib in the treatment of metastatic renal cell carcinoma: A case report.Oncol Lett. 2023 Dec 20;27(2):66. doi: 10.3892/ol.2023.14199. eCollection 2024 Feb. Oncol Lett. 2023. PMID: 38192652 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials